AcroPak capsule filter - Fluorodyne II membrane
High flow rate and low protein adsorption, with a wide range of chemical compatibility! Achieved high-speed processing of clean batches.
The product features high flow rates, low protein adsorption, low preservative binding, broad chemical compatibility, and heat resistance. The "AcroPak 200 Fluorodyne II" capsules enable high-speed processing of clean batches. To minimize leachables, they are manufactured without adhesives and prevent vapor lock through the primary air vent. 【Features of AcroPak 20, 200, Fluorodyne II】 ■ Efficiently processes liquids up to 20 L ■ The "AcroPak 20 filter" is designed for small to medium-scale filtration ■ Prevents vapor lock through the primary air vent ■ Manufactured without adhesives to minimize leachables *For more details, please refer to the PDF document or feel free to contact us.
basic information
【AcroPak 400・800・Fluorodyne II Features】 ■ Scale-up to 100 L for downstream process applications ■ High flow rate, low protein binding, broad chemical compatibility, heat resistance ■ Suitable for large volume sample filtration applications requiring PVDF membranes *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Model number/Brand name
AcroPak capsule filter, Fluorodyne II membrane
Applications/Examples of results
【Application】 ■ Filtration of media and buffers ■ Essential filtration of water used in laboratories ■ Filtration of high-viscosity solutions, solutions containing many fine particles, and media containing serum ■ Use in many solutions containing low-concentration proteins and preservatives * For more details, please refer to the PDF materials or feel free to contact us.
Recommended products
Distributors
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.